NCT03560908 2025-05-01
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Withdrawn
Clinical Trials
5 trialsNCT01826838 2022-02-24
BrUOGPR255
Brown University
Phase 1 Withdrawn
NCT03414450 2018-10-25
Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 1 Withdrawn
NCT02680951 2018-04-19
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Emory University
Phase 1 Withdrawn
NCT00324077 2016-02-17
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
Bristol-Myers Squibb
Phase 1 Withdrawn